TSPO PET With 18F-GE-180 to Differentiate Variants of Multiple Sclerosis: Relapsing-Remitting Multiple Sclerosis, Tumefactive Demyelination, and Baló's Concentric Sclerosis.
Clin Nucl Med. 2020;10.1097/RLU.0000000000003220. doi:10.1097/RLU.0000000000003220 [published online ahead of print, 2020 Aug 11]
|Authors/Editors:||Völk S, Unterrainer M, Albert NL, Havla J, Gerdes LA, Schumacher M, Brendel M, Kaiser L, Adorjan K, Rupprecht R, Bartenstein P, Kümpfel T, Danek A.|
PET targeting the translocator protein (TSPO) expression is an interesting approach to detect neuroinflammation, as TSPO is upregulated in activated macrophages and microglia. Considering the variable pathophysiology of multiple sclerosis (MS) variants, we compare TSPO PET using F-GE-180 in 3 different demyelinating diseases of the central nervous system: relapsing-remitting MS, tumefactive MS, and Baló's concentric sclerosis. Visualization of neuroinflammation and its PET patterns in addition to MRI may contribute to accurate distinction and monitoring of central nervous system demyelination.